Navigation Links
Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
Date:3/30/2009

et="_new">NPP@idispharma.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that closing conditions under our agreement with Merck & Co., Inc. may not be met, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop IPLEX(TM) may be unsuccessful our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Insmed Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
2. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
3. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
4. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
5. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
6. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
7. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
8. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
9. Insmed to Seek Shareholder Approval for Reverse Split
10. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
11. Insmed to Present at Biosimilars 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015  This research service analyzes the various ... and biotechnology industry. The deals are analyzed based on ... based on the geographic region and buyer types. The ... takes into account various deal multiples such as enterprise ... target company. Executive Summary ...
(Date:4/21/2015)... Texas , April 21, 2015 ... grow from $313.0 million in 2014 to $605.1 million by ... under consideration. Browse through the TOC of ... an in-depth analysis of the industry trends and segments, ... http://www.micromarketmonitor.com/market/north-america-bio-stimulants-6850160039.html Early buyers will ...
(Date:4/21/2015)... 2015 AbilTo, Inc., the nation,s leading digital ... has been accepted as a presentation to be included ... place on June 5-6, 2015 in Boston, Massachusetts ... Diabetes Association, the cost of diabetes to the American ... result of increased inpatient, outpatient, and pharmacy costs, the ...
(Date:4/21/2015)... YORK , April 21, 2015 Immune ... that its Board of Directors has elected Rene-Pierre ... the Transaction and Pricing Committee, with oversight on strategic ... member of the Audit Committee, the Compensation Committee and ... his election, Mr. Azria commented: "I have a long-time ...
Breaking Biology Technology:Funding Patterns in the Global Pharma and Biotech Industry 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4
... 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, ... operations in China and the United,States, today announced that ... Most,Innovative Enterprises" and its CEO Dr. Ge Li was ... Chinese Enterprises" at the 8th China,Enterprise Innovation Forum held ...
... access to 'Best Practices for Long-term Jatropha ... Rajagopal's highly successful November 2007 position paper ... is being offered. It emphasizes the need ... it nears commercialization as a viable alternative ...
... Australia, July 10 Cytopia (ASX: CYT),announced today ... Scientific,Advisor to the company., Based in California, ... executive management team, on a part-time basis during ... has held global,leadership roles at Glaxo Wellcome and ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 3Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 4Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist 2
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... 2010) -- A cell devotes a significant amount of ... sorts of chromosomal rearrangements characteristic of many cancers. Assays ... needed in order to understand the individual genes and the ... issue of Cold Spring Harbor Protocols , ...
... developed by Laszlo Otvos, a research professor of ... looks to be a highly-effective therapy against infections ... Otvos and his collaborators found that when ... than current antimicrobial chemotherapy measures in treating multidrug-resistant ...
... Park, MD (August 31, 2010) -- A new imaging ... of the eyeball (ocular fundus) may pave the way ... of the eye, such as age-related macular degeneration and ... Review of Scientific Instruments, which is published ...
Cached Biology News:Cold Spring Harbor Protocols features chromosomal rearrangement, gene copy number methods 2LEDs illuminate eye for ocular disease screening 2
... This antibody is specific for human cardiac troponin ... the Ca-binding signals responsible for contraction of cardiac ... troponin complex in human cells. It also cross-reacts ... Antigen: Highly purified human ...
...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Biology Products: